Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression

Table 1 Clinical correlation of Fibulin-5 expression in HCC

Clinicopathologic features		Total No. of patients, n = 86	No. of patients		P
			Fibulin-5^low	Fibulin-5^high
Age (y)	<50	27	15	12	0.208
Age (y)	≥50	59	41	18	0.208
Sex	Male	69	44	25	0.597
Sex	Female	17	12	5	0.597
HBV	Absent	30	19	11	0.800
HBV	Present	56	37	19	0.800
Serum AFP level (ng/mL)	<400	34	24	10	0.389
Serum AFP level (ng/mL)	≥400	52	32	20	0.389
Tumor size (cm)	<5	30	22	8	0.242
Tumor size (cm)	≥5	56	34	22	0.242
No. of tumor nodules	1	66	49	17	0.001*
No. of tumor nodules	≥2	20	7	13	0.001*
Cirrhosis	Absent	37	26	11	0.384
Cirrhosis	Present	49	30	19	0.384
Venous infiltration	Absent	42	33	9	0.011*
Venous infiltration	Present	44	23	21	0.011*
Edmondson-Steiner grading	I + II	29	24	5	0.014*
Edmondson-Steiner grading	III + IV	57	32	25	0.014*
TNM tumor stage	I + II	61	44	17	0.033*
	III + IV	25	12	13

HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis. *Statistically significant.

ISSN: 1471-2407